AUDDIA INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AUDDIA INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $110.9K | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $458.8K | Mar 31, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.69M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($8.72M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($8.81M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($6.90M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.48M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($4.05M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($5.23M) | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.70M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($7.92M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($7.48M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($6.72M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.57M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($2.38M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($3.80M) | Mar 31, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.02M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $781.0K | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $654.9K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $399.5K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $106.1K | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $312.6K | Mar 31, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.63M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($5.09M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($4.50M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($4.75M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.47M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($1.99M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($2.95M) | Mar 31, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.2K | Mar 5, 2025 |
| FY2024 | Dec 31, 2023 | $2.4K | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $3.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $80.4K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.7K | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $13.0K | Mar 31, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.20M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.30M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $4.40M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $6.11M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.63M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.31M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.86M | Mar 31, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $967.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $604.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $3.98M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $2.26M | Apr 1, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.24M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $4.69M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $420.4K | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $3.85M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $9.41M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($13.10M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($9.23M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($5.75M) | Mar 31, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($97.28M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($89.43M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($80.54M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($71.74M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($64.84M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($51.36M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | ($47.31M) | Mar 31, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.19M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.71M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $804.6K | Mar 5, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (57) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (57) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (12) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.10M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 397,731 | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 854,162 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 506,198 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 12.42M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 485,441 | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 470,658 | Mar 31, 2021 |